Short Report: Seroreactivity to a large panel of field-derived plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria

American Journal of Tropical Medicine and Hygiene

Volumn 92, Issue 1, 2015, Pages 9-12

  Bailey, Jason A ^a   Pablo, Jozelyn ^b   Niangaly, Amadou ^c,e   Travassos, Mark A ^a   Ouattara, Amed ^a   Coulibaly, Drissa ^c,e   Laurens, Matthew B ^a   Takala Harrison, Shannon L ^a   Lyke, Kirsten E ^a   Skinner, Jeff ^d   Berry, Andrea A ^f   Jasinskas, Algis ^b   Nakajima Sasaki, Rie ^b   Kouriba, Bourema ^e   Thera, Mahamadou A ^c,e   Felgner, Philip L ^b   Doumbo, Ogobara K ^e   Plowe, Christopher V ^a  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BAMAKO   (Mali)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e and Technologies of Bamako   (Mali)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

APICAL MEMBRANE ANTIGEN 1; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; PARASITE ANTIGEN; PROTEIN VARIANT; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; MEMBRANE PROTEIN; PROTOZOAL PROTEIN;

ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; DRUG EFFICACY; EXPOSURE; HUMAN; MALARIA; MALI; MALIAN; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEIN MICROARRAY; ANIMAL; IMMUNOLOGY; MALARIA FALCIPARUM; SEASON;

MALIA; PLASMODIUM FALCIPARUM;

ADULT; ANIMALS; ANTIGENS, PROTOZOAN; CHILD; HUMANS; MALARIA, FALCIPARUM; MEMBRANE PROTEINS; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; SEASONS;

EID: 84920561267     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.14-0140     Document Type: Article

References (21)

1. Ouattara A, Mu J, Takala-Harrison S, Saye R, Sagara I, Dicko A, Niangaly A, Duan J, Ellis RD, Miller LH, Su XZ, Plowe CV, Doumbo OK, 2010. Lack of allele-specific efficacy of a bivalent AMA1 malaria vaccine. Malar J 9: 175.
2. Takala SL, Plowe CV, 2009. Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol 31: 560-573.
3. Hviid L, 2005. Naturally acquired immunity to Plasmodium falciparum malaria in Africa. Acta Trop 95: 270-275.
4. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Ouattara A, Kone AK, Guindo AB, Traore K, Traore I, Kouriba B, Diallo DA, Diarra I, Daou M, Dolo A, Tolo Y, Sissoko MS, Niangaly A, Sissoko M, Takala-Harrison S, Lyke KE, Wu Y, Blackwelder WC, Godeaux O, Vekemans J, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, House B, Lanar DE, Dutta S, Heppner DG Jr, Plowe CV, 2011. A field trial to assess a blood-stage malaria vaccine. N Engl J Med 365: 1004-1013.
5. Sagara I, Dicko A, Ellis RD, Fay MP, Diawara SI, Assadou MH, Sissoko MS, Kone M, Diallo AI, Saye R, Guindo MA, Kante O, Niambele MB, Miura K, Mullen GE, Pierce M, Martin LB, Dolo A, Diallo DA, Doumbo OK, Miller LH, Saul A, 2009. A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in Mali. Vaccine 27: 3090-3098.
6. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Kone AK, Guindo AB, Traore K, Dicko A, Sagara I, Sissoko MS, Baby M, Sissoko M, Diarra I, Niangaly A, Dolo A, Daou M, Diawara SI, Heppner DG, Stewart VA, Angov E, Bergmann-Leitner ES, Lanar DE, Dutta S, Soisson L, Diggs CL, Leach A, Owusu A, Dubois MC, Cohen J, Nixon JN, Gregson A, Takala SL, Lyke KE, Plowe CV, 2008. Safety and immunogenicity of anAMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized control trial. PLoS One 3: e1465.
7. Takala SL, Coulibaly D, Thera MA, Dicko A, Smith DL, Guindo AB, Kone AK, Traore K, Ouattara A, Djimde AA, Sehdev PS, Lyke KE, Diallo DA, Doumbo OK, Plowe CV, 2007. Dynamics of polymorphism in a malaria vaccine antigen at a vaccinetesting site in Mali. PLoS One 4: e93.
8. Takala SL, CoulibalyD, Thera MA, Batchelor AH, CummingsMP, Escalante AA, Ouattara A, Traore K, Niangaly A, Djimde AA, Doumbo OK, Plowe CV, 2009. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci Transl Med 2: 2ra5.
9. Ouattara A, Takala-Harrison S, Thera MA, Coulibaly D, Niangaly A, Saye R, Tolo Y, Dutta S, Heppner DG, Soisson L, Diggs CL, Vekemans J, Cohen J, Blackwelder WC, Dube T, Laurens MB, Doumbo OK, Plowe CV, 2013. Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis 207: 511-519.
10. Doolan DL, Mu Y, Unal B, Sundaresh S, Hirst S, Valdez C, Randall A, Molina D, Liang X, Freilich DA, Oloo JA, Blair PL, Aguiar JC, Baldi P, Davies DH, Felgner PL, 2008. Profiling humoral immune responses to P. falciparum infection with protein microarrays. Proteomics 8: 4680-4694.
11. Barry AE, Trieu A, Fowkes FJ, Pablo J, Kalantari-Dehaghi M, Jasinskas A, Tan X, Kayala MA, Tavul L, Siba PM, Day KP, Baldi P, Felgner PL, Doolan DL, 2011. The stability and complexity of antibody responses to the major surface antigen of Plasmodium falciparum are associated with age in a malaria endemic area. Mol Cell Proteomics 10: M111.
12. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, Molina DM, Burk CR, Waisberg M, Jasinskas A, Tan X, Doumbo S, Doumtabe D, Kone Y, Narum DL, Liang X, Doumbo OK, Miller LH, Doolan DL, Baldi P, Felgner PL, Pierce SK, 2010. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proc Natl Acad Sci USA 107: 6958-6963.
13. Trieu A, Kayala MA, Burk C, Molina DM, Freilich DA, Richie TL, Baldi P, Felgner PL, Doolan DL, 2011. Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens. Mol Cell Proteomics 10: M111.
14. Baum E, Badu K, Molina DM, Liang X, Felgner PL, Yan G, 2013. Protein microarray analysis of antibody responses to Plasmodium falciparum in western Kenyan highland sites with different transmission levels. PLoS One 8: e82246.
15. Ouattara A, Takala-Harrison S, Thera MA, Coulibaly D, Niangaly A, Saye R, Tolo Y, Dutta S, Heppner DG, Soisson L, Diggs CL, Vekemans J, Cohen J, Blackwelder WC, Dube T, Laurens MB, Doumbo OK, Plowe CV, 2013. Molecular basis of allele-specific efficacy of a blood-stage malaria vaccine: vaccine development implications. J Infect Dis 207: 511-519.
16. Takala SL, Smith DL, Thera MA, Coulibaly D, Doumbo OK, Plowe CV, 2007. Short report: rare Plasmodium falciparum merozoite surface protein 1 19-kda (msp-1(19)) haplotypes identified in Mali using high-throughput genotyping methods. Am J Trop Med Hyg 76: 855-859.
17. Davies DH, Liang X, Hernandez JE, Randall A, Hirst S, Mu Y, Romero KM, Nguyen TT, Kalantari-Dehaghi M, Crotty S, Baldi P, Villarreal LP, Felgner PL, 2005. Profiling the humoral immune response to infection by using proteome microarrays: high-throughput vaccine and diagnostic antigen discovery. Proc Natl Acad Sci USA 102: 547-552.
18. Thera MA, Doumbo OK, Coulibaly D, Diallo DA, Sagara I, Dicko A, Diemert DJ, Heppner DG, Jr., Stewart VA, Angov E, Soisson L, Leach A, Tucker K, Lyke KE, Plowe CV, 2006. Safety and allele-specific immunogenicity in Malian adults: results of a phase I randomized trial. PLoS Clin Trials 1: e34.
19. Thera MA, Doumbo OK, Coulibaly D, Laurens MB, Kone AK, Guindo AB, Traore K, Sissoko M, Diallo DA, Diarra I, Kouriba B, Daou M, Dolo A, Baby M, Sissoko MS, Sagara I, Niangaly A, Traore I, Olotu A, Godeaux O, Leach A, Dubois MC, Ballou WR, Cohen J, Thompson D, Dube T, Soisson L, Diggs CL, Takala SL, Lyke KE, House B, Lanar DE, Dutta S, Heppner DG, Plowe CV, 2010. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized control trial. PLoS One 5: e9041.
20. Sboner A, Karpikov A, Chen G, Smith M, Mattoon D, Freeman-Cook L, Schweitzer B, Gerstein MB, 2009. Robust-linearmodel normalization to reduce technical variability in functional protein microarrays. J Proteome Res 8: 5451-5464.
21. Vafa M, Troye-Blomberg M, Anchang J, Garcia A, Migot-Nabias F, 2008. Multiplicity of Plasmodium falciparum infection in asymptomatic children in Senegal: relation to transmission, age and erythrocyte variants. Malar J 7: 17.